October 2010- Volume 6, Issue 10

October 2010

In this Issue

Instruments & Informatics

German groups improve genetic workflows

German groups improve genetic workflows

IMGM Laboratories and the Center for Human Genetics and Laboratory Medicine to develop workflows for use of 454 Sequencing Systems in human genetics

From Russia with love

From Russia with love

How three scientists from the former Soviet Union are leading teams to discover new therapies for prostate cancer

An intrepid reporter for miRNA research

An intrepid reporter for miRNA research

Sigma Life Science and SwitchGear Genomics to co-develop simplified novel microRNA target validation system

Geospiza links with SAIC-Frederick

Geospiza links with SAIC-Frederick

Partners will collaborate to accelerate cancer research with PacBio RS

Diagnostics

Tapping into tissue trove

Tapping into tissue trove

American, Danish and Swiss forces combine to develop molecular diagnostics platform for large-scale sequence analysis of FFPE tissue samples

An ounce of prevention

An ounce of prevention

Alzheimer's Prevention Initiative launches two clinical trials that will apply biomarkers to test the efficacy of pre-symptomatic treatments

On the trail of TB

On the trail of TB

Researchers find new genomic signature for TB that can predict future patients

Emerald BioStructures and SomaLogic forge strategic collaboration

Emerald BioStructures and SomaLogic forge strategic collaboration

Former deCODE company will apply its X-ray crystallography platform to SOMAmer-target complexes

Contract Services

Foursome aims to be outsourcing force

Foursome aims to be outsourcing force

Out of the merger of four portfolio companies will arise a new global biopharmaceutical development service organization

Encorium seeks world domination

Encorium seeks world domination

Acquisition of Progenitor gives the CRO added vaccine development capabilities on two continents

Cyprotex acquisition of Apredica includes assets from Cellumen

Cyprotex acquisition of Apredica includes assets from Cellumen

Combination expands presence in North America and in the fast-growing predictive toxicology market

Friends, not foes

Friends, not foes

Former rivals MDCI and CDSS join forces to streamline regulatory approvals in U.S. and Europe

Omics & Systems Biology

BMS picks pearl from Emerald City

BMS picks pearl from Emerald City

Acquisition of Seattle- based biotech ZymoGenetics strengthens hepatitis C program, virology portfolio

Alnylam and partners silence gene implicated in Parkinson’s disease

Alnylam and partners silence gene implicated in Parkinson’s disease

New research published in journal PLoS shows silencing of alpha-synuclein in the substantia nigra of non-human primates with an RNAi therapeutic

Reduce, refine and replace

Reduce, refine and replace

Johns Hopkins and Agilent team up to pursue alternatives to the use of animal models in toxicity research

X-MAN to the rescue

X-MAN to the rescue

Horizon Discovery providing Sanger Institute human cancer models for research

Great expectations

Great expectations

With exclusive license to novel Harvard methodologies for nucleic acid analysis, GnuBIO says it’s ready to crack the $100 genome

Research & Development

Deep in the heart of Texas

Deep in the heart of Texas

Ross Perot pledges $20 million to MD Anderson to pursue personalized cancer therapies

Pfizer adds wrinkle to FoldRx

Pfizer adds wrinkle to FoldRx

Pharma acquires pharmaceutical company to boost its specialty care business

Specializing is Swedes’ strategy

Specializing is Swedes’ strategy

Swedish pharma Meda signs $350 million acquisition deal for U.S.- based Alaven

Anchors aweigh

Anchors aweigh

Anchor Therapeutics enters into collaboration with Ortho-McNeil-Janssen for its pepducin technology

Feature

Of a mind to learn and connect

Of a mind to learn and connect

Neuroscience 2010 show aims to stimulate thought and provide networking for some 30,000 neuroscience professionals in sunny San Diego

Special Reports

Biomarkers: How good a test are they?

Biomarkers: How good a test are they?

It seems that barely a month goes by without a headline touting a new way of detecting, understanding or treating cancer. Whether it is a newly identified gene or protein in the blood, tracing biological fingerprints, known as biomarkers, can be a valuable and rapidly growing part of medical research.

Report: Cancer diagnostics market could hit $90 million by 2014

Report: Cancer diagnostics market could hit $90 million by 2014

Cancer treatment is one area where the era of personalized medicine is arriving, according to market research publisher Kalorama Information. In its recent report, “The Worldwide Market for Cancer Diagnostics,” Kalorama predicts a $90 million market for pharmacodiagnostics, tests that determine whether a treatment matches the individual patient, by 2014.

Two are better than one

Two are better than one

The challenges and rewards of developing companion diagnostics for cancer treatment

Global News

New chapter for neurodegenerative diseases unfolds

New chapter for neurodegenerative diseases unfolds

Roche and reMYND, developer of treatments against protein misfolding disorders, jointly pursue disease-modifying programs for Parkinson’s and Alzheimer’s diseases

Back to basics

Back to basics

An international team led by scientists from the Scripps Research Institute, the Swiss Tropical Institute, the Genomics Institute of the Novartis Research Foundation (GNF) and the Novartis Institute for Tropical Diseases has discovered a drug candidate that represents a potentially new class of drugs to treat malaria.

A winning pair of partnerships

A winning pair of partnerships

CRT pursues deals with Bayer Schering Pharma for treating gynecological and oncological diseases and AstraZeneca for broad oncology therapy

One-two punch

One-two punch

Jennerex, Transgene forge partnership to co-develop cancer-fighting virus JX-594

Editor's Focus

Granny’s giggle gone too soon

Granny’s giggle gone too soon

For ddn Chief Editor Amy Swinderman, writing story about efforts to prevent Alzheimer’s disease hits close to home

Commentary

Success is a reliable predictor of failure

Success is a reliable predictor of failure

Two of my favorite industries, pharma and medical devices, are clearly suffering as a result of their long run of success.

Quantitating multiple signaling pathway proteins in preclinical and clinical studies

Quantitating multiple signaling pathway proteins in preclinical and clinical studies

Combining multispectral imaging with advanced image analysis tools to perform tissue cytometry rapidly and on a large scale and using many markers at once has proven to enable a better understanding of the mechanism of disease and potentially better, more precise avenues of treatment.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022